Moderna Inc. (NASDAQ:MRNA) is one of them 10 stocks dominated today’s market action.
Moderna extended a two-day losing streak on Wednesday, jumping 15.99 percent to $57.80 apiece after settling a four-year legal dispute with two biopharmaceutical companies over alleged patent infringement of their lipid nanoparticle (LNP) delivery technology.
In a statement, Moderna Inc. (NASDAQ: MRNA) said it has agreed to pay a total of $2.5 billion to Arbutus Biopharma Corporation and Genevant Sciences GmbH to settle LNP’s patent infringement lawsuit, of which $950 million will be paid in the third quarter, while the remaining $3 billion will be pending an appeal. the circuit
Photo by Artem Poudrez in Pixels
The case centered on allegations by Arbutus and Genevant that Moderna Inc. (NASDAQ: MRNA) used their LNP technology for their SpikeVax and mRESVIA vaccines without their permission.
“If Moderna ultimately prevails in this case, there will be no further payments. Even if, however, the Federal Circuit affirms liability under Section 1498, Moderna has agreed to pay an additional $1.3 billion within 90 days of that decision, depending on the scope of the decision.”
“After that, if Moderna ultimately prevails through other proceedings — whether in remand, in the Supreme Court, or on remand to a district court — Arbutus/Genevant will refund the full payment plus interest.”
Moderna Inc. (NASDAQ: MRNA ) said it expects to record $950 million in settlement charges in the first quarter of the year and end the year with $4.5 billion to $5 billion in cash and cash equivalents.
While we acknowledge the potential of MRNA as an investment, our belief is that some AI stocks hold great promise for delivering high returns and limited risk. If you’re looking for a very cheap AI stock that’s also a big beneficiary of Trump’s tariffs and onsuring, check out our free report Best short-term AI stocks.
Read more: 30 stocks that should double in 3 years and 11 Secret AI Stocks to Buy Right Now.
Disclosure: None. Follow the inside port on Google News.
